Boehringer Ingelheim has published its financial results for the first half of 2012, during which it experienced strong year-on-year growth. The company’s currency-adjusted sales total for the six months came to 7.1 billion euros (5.58 billion pounds), up by 6.8 percent annually, thanks in large part to the momentum of products such as Spiriva, Combivent, Pradaxa and Trajenta. Emerging markets and the US were highlighted as delivering particularly strong performances, but the company warned that depressed macroeconomic conditions will create challenges during the second half of the year.
